Clinical Trials
77
8 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1905
Active, not recruiting
2
2.6%
Completed
39
50.6%
Enrolling By Invitation
1
1.3%
Not yet recruiting
5
6.5%
Recruiting
10
13.0%
Terminated
1
1.3%
Unknown
17
22.1%
Withdrawn
2
2.6%
No approval data available
- Researchers used high-resolution atomic force microscopy and molecular dynamics simulations to directly visualize DNA-DNA recognition for the first time, confirming a mechanism proposed more than 20 years ago. - The study shows positively charged divalent ions such as magnesium and calcium act as molecular bridges that hold neighboring DNA helices in a groove-to-groove alignment. - The team identified specific DNA sequence motifs that form hotspots where pairing occurs more readily, regions that may matter when mutations disrupt normal cellular processes in cancer. - Findings, published in Nucleic Acids Research, may inform understanding of chromosome organization and support design of DNA origami for targeted drug delivery.
- Cecil George Paine, a University of Sheffield pathologist, performed the first documented topical application of unpurified penicillin in 1930 to treat human infections. - Paine successfully treated eye infections in two babies and a miner, sharing his findings with Alexander Fleming and Howard Florey. - Sir Howard Florey later purified penicillin and conducted the first clinical trial of the drug in 1941, a breakthrough estimated to have saved 82 million lives worldwide. - A commemorative plaque has been installed at the University of Sheffield's Jessop Building to honour Paine's little-known but pioneering contribution.
- University of Sheffield students from the Julia Garnham Centre created seven comprehensive guides covering extremely rare genetic conditions, now available globally through the charity Unique. - The guides translate complex genomic data into accessible information, offering families clarity after diagnoses that often leave them with unanswered questions. - For one family affected by TRIO-Related Neurodevelopmental Disorder, the student-produced booklet replaced years of explaining the condition to doctors and provided hope by showing adults living fulfilling lives. - The collaboration between the University of Sheffield, Sheffield Children's NHS Foundation Trust, and Unique demonstrates an innovative co-creative model that may expand to help more families in the future.
- The National Institute for Health and Care Research has launched the UK's first Parkinson's Disease Translational Research Collaboration, bringing together 17 centers of excellence to accelerate treatment and diagnostic development. - The collaboration addresses critical gaps in experimental medicine and early clinical trials for Parkinson's disease, which affects over 166,000 people in the UK. - Led by Professor Oliver Bandmann at Sheffield Teaching Hospitals, the initiative aims to bridge the gap between laboratory discoveries and patient benefits through coordinated translational research. - The PD-TRC represents the eighth NIHR Translational Research Collaboration and will foster partnerships between academia, NHS services, industry, and patient organizations to reduce research inequalities across the UK.
- Scientists from the University of Sheffield, UCL Great Ormond Street Institute, and Queen's University Belfast are developing a stem cell therapy to provide a permanent cure for Hirschsprung disease, a rare condition affecting newborns' digestive systems. - The £2.7 million UKRI-funded project has created a method to grow missing enteric nervous system nerves from human stem cells in just six days, nearly twice as fast as existing methods. - The lab-grown cells have demonstrated effectiveness in restoring gut function in patient tissue samples and are "off-the-shelf" ready, meaning they can be frozen and transported to hospitals across the UK. - Early health economic modeling suggests this one-time cell therapy could be highly cost-effective compared to the current treatment approach of repeat surgeries and specialized care.
- University of Sheffield scientists have been awarded £1 million by the Engineering and Physical Sciences Research Council to develop a novel drug delivery system combining Cold Atmospheric Plasma with molecularly imprinted polymers for targeted cancer treatment. - The three-year project aims to create "smart" hydrogels that can deliver chemotherapy directly to post-surgical sites in glioblastoma patients, as well as treat severe inflammatory skin diseases and fungal infections. - The innovative approach uses molecular imprinting to grow hydrogels around drug molecules, creating custom-fitted cavities that can hold complex drugs previously impossible to use in such systems. - The technology enables on-demand, controlled drug release through plasma activation, offering dual benefits of targeted therapy and tissue oxygenation for accelerated healing.
- Scientists at the University of Sheffield have developed M102, a new drug that protects nerve cells damaged by motor neurone disease and showed improvement in movement and nerve function in preclinical mouse studies. - The drug works by activating two protective cellular systems, NRF2 and HSF1, which help nerves combat stress, reduce inflammation, and clear damaged proteins. - Researchers are now preparing to advance M102 to human clinical trials, offering hope for the approximately 5,000 people in the UK living with MND, a condition that typically leads to death within two to five years. - The preclinical study, published in Molecular Neurodegeneration, demonstrated that M102 not only slowed MND progression in mice but also protected laboratory-grown motor neurones from damage caused by MND patient cells.
- The £2 million Triceps trial has recruited 200 of its target 270 patients to test transcutaneous vagus nerve stimulation (TVNS) for post-stroke arm and hand weakness recovery. - The non-invasive treatment uses a wearable device with earpiece to deliver electrical pulses to the vagus nerve during home-based rehabilitation therapy. - Around one-third of stroke survivors experience permanent arm and hand weakness, making this potential treatment significant for improving independence and quality of life. - The double-blind trial expanded from 243 to 270 patients following interim analysis and needs just 65 more participants to complete recruitment across 19 NHS centers.
- Researchers at the University of Sheffield and MRC have identified specific antibodies that protect children against Strep A, a bacterial infection that kills 500,000 people annually worldwide. - The study tracked children in The Gambia and discovered that while maternal protection fades, young children rapidly develop immune responses to parts of the bacteria. - These findings, published in Nature Medicine, represent the first identification of protective antibodies in humans and could enable development of a vaccine to save hundreds of thousands of lives. - The breakthrough addresses a critical knowledge gap that has historically hindered vaccine development against this potentially deadly bacterial infection.
- The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first-ever human trial of regenerative cell therapy for sensorineural hearing loss, marking a significant milestone in auditory medicine. - Rinri Therapeutics' Rincell-1 therapy is designed to regenerate damaged auditory neurons, targeting a condition for which no current treatment exists beyond symptom management. - The randomized, open-label trial will involve 20 patients across three UK research centers, with clinical proof-of-concept data expected within 12 months of trial initiation. - The therapy represents a potential breakthrough for treating neural hearing loss by replacing damaged sensory cells in the inner ear to restore hearing function.
